Research graph
References from OligoM-Cancer: A multidimensional information platform for deep phenotyping of heterogenous oligometastatic cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21834
10.3322/caac.21834 · External reference
10.1016/j.cell.2023.03.003
10.1016/j.cell.2023.03.003 · External reference
10.1200/jco.1995.13.1.8
10.1200/jco.1995.13.1.8 · External reference
10.1038/nrclinonc.2011.44
10.1038/nrclinonc.2011.44 · External reference
Stereotactic ablative radiotherapy for gynecological oligometastatic and oligoprogessive tumors
10.1001/jamaoncol.2024.1796 · 2024 · External reference
Benchmarking outcomes for molecularly characterized synchronous oligometastatic non-small-cell lung cancer reveals EGFR mutations to be associated with longer overall survival
10.1200/po.22.00540 · 2023 · External reference
Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials
10.1200/jco.22.00644 · 2022 · External reference
Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer
2024 · External reference
10.1016/j.ctrv.2022.102462
10.1016/j.ctrv.2022.102462 · External reference
10.1001/jamanetworkopen.2020.26312
10.1001/jamanetworkopen.2020.26312 · External reference
Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document
10.1016/j.radonc.2020.04.003 · 2020 · External reference
Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline Part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions
10.1097/ju.0000000000003890 · 2024 · External reference
Treatment of oligometastatic non-small cell lung cancer: an ASTRO/ESTRO clinical practice guideline
10.1016/j.prro.2023.04.004 · 2023 · External reference
Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report
10.1016/j.jtho.2019.07.025 · 2019 · External reference
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups
10.1016/s1470-2045(23)00286-3 · 2023 · External reference
Definition and diagnosis of oligometastatic bladder cancer: a delphi consensus study endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty
10.1016/j.eururo.2023.05.005 · 2023 · External reference
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
10.1016/s1470-2045(19)30718-1 · 2020 · External reference
Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: an analysis of the national cancer database
10.1016/j.surg.2021.12.029 · 2022 · External reference
Liquid biopsy in oligometastatic prostate cancer-a biologist's point of view
10.3389/fonc.2019.00775 · 2019 · External reference
Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a multicenter, randomized Phase II Trial
2024 · External reference
Retooling treatment in oligometastatic oesophageal cancer
10.1016/s2468-1253(23)00362-x · 2024 · External reference
Imaging and its impact on defining the oligometastatic state
10.1016/j.semradonc.2021.03.006 · 2021 · External reference
Evaluation of concurrent chemoradiotherapy for survival outcomes in patients with synchronous oligometastatic esophageal squamous cell carcinoma
10.1001/jamanetworkopen.2022.44619 · 2022 · External reference
Treatment of oligo-metastatic pancreatic ductal adenocarcinoma to the liver: is there a role for surgery? A narrative review
10.1097/js9.0000000000001665 · 2024 · External reference
European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
10.1016/j.ejca.2024.114062 · 2024 · External reference
Determining planning priorities for SABR for oligometastatic disease: a secondary analysis of the SABR-COMET Phase II randomized trial
10.1016/j.ijrobp.2022.01.002 · 2022 · External reference
Changes in the characteristics of patients treated for brain metastases with repeat stereotactic radiotherapy (SRT): a retrospective study of 184 patients
10.1186/s13014-023-02200-z · 2023 · External reference
CLAMP - a toolkit for efficiently building customized clinical natural language processing pipelines
10.1093/jamia/ocx132 · 2018 · External reference
ECharts: A declarative framework for rapid construction of web-based visualization
10.1016/j.visinf.2018.04.011 · 2018 · External reference
10.1093/nar/gkx1008
10.1093/nar/gkx1008 · External reference
10.1016/j.jgg.2017.04.006
10.1016/j.jgg.2017.04.006 · External reference
HMDD v4.0: a database for experimentally supported human microRNA-disease associations
10.1093/nar/gkad717 · 2024 · External reference
10.1093/nar/gkad986
10.1093/nar/gkad986 · External reference
MethMarkerDB: a comprehensive cancer DNA methylation biomarker database
10.1093/nar/gkad923 · 2024 · External reference
10.1093/nar/gkad880
10.1093/nar/gkad880 · External reference
10.1016/j.semcancer.2019.08.026
10.1016/j.semcancer.2019.08.026 · External reference
Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study
10.1186/s12885-019-6399-1 · 2019 · External reference
The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited
10.1016/j.eururo.2020.12.040 · 2021 · External reference
High-metastatic melanoma cells promote the metastatic capability of low-metastatic melanoma cells via exosomal transfer of miR-411-5p
10.3389/fonc.2022.895164 · 2022 · External reference
Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)
10.1002/cncr.30058 · 2016 · External reference
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs
10.1371/journal.pone.0050141 · 2012 · External reference
10.18632/oncotarget.2920
10.18632/oncotarget.2920 · External reference
Large language models for preventing medication direction errors in online pharmacies
2024 · External reference
CRPMKB: a knowledge base of cancer risk prediction models for systematic comparison and personalized applications
10.1093/bioinformatics/btab850 · 2022 · External reference
10.1016/j.csbj.2021.09.001
10.1016/j.csbj.2021.09.001 · External reference
MedML: Fusing medical knowledge and machine learning models for early pediatric COVID-19 hospitalization and severity prediction
10.1016/j.isci.2022.104970 · 2022 · External reference
Explainable AI for estimating pathogenicity of genetic variants using large-scale knowledge graphs
2023 · External reference
KG-LIME: predicting individualized risk of adverse drug events for multiple sclerosis disease-modifying therapy
10.1093/jamia/ocae155 · 2024 · External reference
10.1097/js9.0000000000000987
10.1097/js9.0000000000000987 · External reference
Performance of ChatGPT on Chinese national medical licensing examinations: a five-year examination evaluation study for physicians, pharmacists and nurses
10.1186/s12909-024-05125-7 · 2024 · External reference
Exploring the potential of artificial intelligence to enhance the writing of english academic papers by non-native english-speaking medical students - the educational application of ChatGPT
10.1186/s12909-024-05738-y · 2024 · External reference
The use of chatbots in head and neck mucosal malignancy treatment recommendations
10.1002/ohn.818 · 2024 · External reference
Challenging ChatGPT 3.5 in senology-an assessment of concordance with breast cancer tumor board decision making
10.3390/jpm13101502 · 2023 · External reference
RARPKB: a knowledge-guide decision support platform for personalized robot-assisted surgery in prostate cancer
10.1097/js9.0000000000001290 · 2024 · External reference
PCAO2: an ontology for integration of prostate cancer associated genotypic, phenotypic and lifestyle data
2024 · External reference
